The diagnostic validity of DLBCL biomarkers was validated by ROC analysis, and the results clearly showed that CDC6, CDC20, KIF20A, STIL, and TOP2A were specific and sensitive in diagnosing DLBCL. This evidence concerns the gene KIF20A and diffuse large B-cell lymphoma.